Hangzhou Sciwind Biosciences Co., Ltd.

杭州先为达生物科技股份有限公司

Biopharmaceutical company developing weight management therapeutics for obesity and related diseases, including GLP-1 injectable ecnoglutide for overweight/obesity, T2DM, MASH and OSA, with one core product and seven pipeline products; operations in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Chapter 18A biotech